Japanese Pharma Stock Sinks Amid COVID-19 Treatment

The drug was originally effective against SARS-CoV-1

Deputy Editor
Mar 10, 2020 at 10:27 AM
facebook twitter linkedin

Shares of AIM Immunotech Inc (NYSE:AIM) were last seen trading down 22.5% at $4.73, despite yesterday announcing that the National Institute of Infectious Diseases (NIID) in Japan will begin testing its drug Ampligen, a broad-spectrum antiviral, as a potential treatment for the new coronavirus outbreak. Researchers are optimistic about the efficacy of this new treatment due to the drugs previous positive reaction with the original SARS coronavirus (SARS-CoV-1).

Despite today's plunge, the stock is up a whopping 644% year-to-date and earlier last week saw a notable bounce off the supportive 10-day moving average. Heading into today, all three covering analysts sport a "buy" recommendation. First thing this morning Alliance Global Partners also chimed in, saying it will maintain its "buy" rating and hiked its price target to $6.50 from $2.76.

Currently, AIM’s short interest of 1.01 million shares accounts for a healthy 13.1% of its total available float. At the equity's average pace of trading, it would take under a week for short sellers to buy back their bearish bets.


Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!